References
- NCCN practice guidelines in oncology: chronic myeloid leukemia. Available from: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
- O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
- Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009;114:4933–4938.
- Palandri F, Iacobucci I, Castagnetti F, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica 2008;93:770–774.
- Kantarjian HM, Smith TL, McCredie KB, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patients’ characteristics and therapy with survival. Blood 1985;66:1366–1375.
- Bleyer A, Barr R, Hayes-Lattin B, et al. Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008;8:288–298.
- Thomas GA, Leonard RCF. How age affects the biology of breast cancer. Clin Oncol 2009; 21:81–85.
- Gugliotta G, Castagnetti F, Palandri F, et al. Gruppo Italiano Malattie Ematologiche dell’Adulto CML Working Party. Frontline imatinib treatment of chronic myeloid leukemia; no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011;117:5591–5599.
- Latagliata R, Breccia M, Carmosino I, et al. “Real-life” results of front-line treatment with imatinib in older patients (>/ = 65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res 2010;34:1472–1475.
- Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973–2009 varying) - Linked To County Attributes - Total U.S., 1969–2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission. Available from: www.seer.cancer.gov
- Mandal R, Bolt DM, Shah BK. Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post- imatinib eras in the US. Acta Oncol 2012 Nov 26. [Epub ahead of print]
- Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009;23:1054–1061.
- Wiggins CL, Harlan LC, Nelson HE, et al. Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med 2010;123:764.e1–9.